Discover our medicines
Our innovative medicines address society’s greatest disease burdens and restore possibility for patients.
Explore our science
Discover how we unravel the mysteries of biology and develop new technologies to fight disease and change lives.
Learn about our impact
Creating a medicine is just the beginning of the journey. Discover how we embrace societal impact as a core business objective.
Novartis Financial Results – Q1 2024
Novartis announced the company’s financial results for the first quarter of 2024.
Latest news
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
The burden of IgAN
IgAN nephropathy (IgAN) is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide. Novartis is working to slow the progression of this disease and extend a dialysis-free life in patients.
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.